kv1 3 biotin antibody Search Results


kv1 3  (Alomone Labs)
93
Alomone Labs kv1 3
GPRC5B-associated macrophage changes involve <t>DLG1/Kv1.3-related</t> signaling. (A) Intersection analysis of GPRC5B-interacting proteins and targets related to senescent macrophages. (B) Co-IP validation of the interaction between GPRC5B and DLG1. (C, D) Western blot analysis of GPRC5B, DLG1, and Kv1.3 protein expression in BMMs from PMO mice and in RAW264.7 cells after GPRC5B knockdown. (E–H) RAW264.7 cells were divided into four groups (n=3): H 2 O 2 +siNC, H 2 O 2 +siGPRC5B, H 2 O 2 +siGPRC5B+oeNC, H 2 O 2 +siGPRC5B+oeDLG1. (E) Western blot analysis of GPRC5B, DLG1, and Kv1.3 protein expression levels in cells. (F) β-Gal staining of RAW264.7 cells. (G) RT-qPCR analysis of IL-1β mRNA expression levels. (H) Flow cytometry analysis of the proportions of CD86-Positive (M1) and CD206-Positive (M2) macrophages in different groups. ** p < 0.01, *** p < 0.001 vs. H 2 O 2 +siNC; ## p < 0.01, ### p < 0.001 vs. H 2 O 2 +siGPRC5B+oeNC.
Kv1 3, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/kv1+3+biotin+antibody/Anti-KV1%2E3+(KCNA3)+(extracellular)-Biotin+Antibody/pmc13529568-125-21-22
Average 93 stars, based on 1 article reviews
kv1 3 - by Bioz Stars, 2026-10
93/100 stars
  Buy from Supplier

Image Search Results


GPRC5B-associated macrophage changes involve DLG1/Kv1.3-related signaling. (A) Intersection analysis of GPRC5B-interacting proteins and targets related to senescent macrophages. (B) Co-IP validation of the interaction between GPRC5B and DLG1. (C, D) Western blot analysis of GPRC5B, DLG1, and Kv1.3 protein expression in BMMs from PMO mice and in RAW264.7 cells after GPRC5B knockdown. (E–H) RAW264.7 cells were divided into four groups (n=3): H 2 O 2 +siNC, H 2 O 2 +siGPRC5B, H 2 O 2 +siGPRC5B+oeNC, H 2 O 2 +siGPRC5B+oeDLG1. (E) Western blot analysis of GPRC5B, DLG1, and Kv1.3 protein expression levels in cells. (F) β-Gal staining of RAW264.7 cells. (G) RT-qPCR analysis of IL-1β mRNA expression levels. (H) Flow cytometry analysis of the proportions of CD86-Positive (M1) and CD206-Positive (M2) macrophages in different groups. ** p < 0.01, *** p < 0.001 vs. H 2 O 2 +siNC; ## p < 0.01, ### p < 0.001 vs. H 2 O 2 +siGPRC5B+oeNC.

Journal: Frontiers in Immunology

Article Title: Integrated single-cell and experimental analyses implicate GPRC5B in macrophage senescence-related alterations in postmenopausal osteoporosis

doi: 10.3389/fimmu.2026.1890278

Figure Lengend Snippet: GPRC5B-associated macrophage changes involve DLG1/Kv1.3-related signaling. (A) Intersection analysis of GPRC5B-interacting proteins and targets related to senescent macrophages. (B) Co-IP validation of the interaction between GPRC5B and DLG1. (C, D) Western blot analysis of GPRC5B, DLG1, and Kv1.3 protein expression in BMMs from PMO mice and in RAW264.7 cells after GPRC5B knockdown. (E–H) RAW264.7 cells were divided into four groups (n=3): H 2 O 2 +siNC, H 2 O 2 +siGPRC5B, H 2 O 2 +siGPRC5B+oeNC, H 2 O 2 +siGPRC5B+oeDLG1. (E) Western blot analysis of GPRC5B, DLG1, and Kv1.3 protein expression levels in cells. (F) β-Gal staining of RAW264.7 cells. (G) RT-qPCR analysis of IL-1β mRNA expression levels. (H) Flow cytometry analysis of the proportions of CD86-Positive (M1) and CD206-Positive (M2) macrophages in different groups. ** p < 0.01, *** p < 0.001 vs. H 2 O 2 +siNC; ## p < 0.01, ### p < 0.001 vs. H 2 O 2 +siGPRC5B+oeNC.

Article Snippet: After blocking, membranes were incubated overnight at 4 °C with primary antibodies against GPRC5B (Thermo Fisher, MA5-63445), DLG1 (BD Biosciences, 610874), Kv1.3 (Alomone Labs, APC-101-B), and β-actin (Abcam, ab8226).

Techniques: Co-Immunoprecipitation Assay, Biomarker Discovery, Western Blot, Expressing, Knockdown, Staining, Quantitative RT-PCR, Flow Cytometry

GPRC5B knockdown ameliorates PMO-associated phenotypes and reveals potential drug targets. GPRC5B-knockdown PMO mice were established and divided into three groups (n=5): PMO (23 months OVX model), PMO+shGPRC5B, and PMO+shGPRC5B+DLG1 inhibitor (DLG1i). The effects of GPRC5B knockdown on bone phenotype, macrophage senescence, and potential drug interactions were subsequently evaluated. (A) Western blot analysis of GPRC5B, DLG1, and Kv1.3 protein expression levels in primary bone marrow-derived macrophages from each group. (B) Representative three-dimensional reconstructed micro-CT images of mice femurs. (C) β-Gal staining of primary BMMs to assess cellular senescence. ***p < 0.001 vs. PMO; ###p < 0.001 vs. PMO+shGPRC5B. (D) Bar plot showing the scores of the top 20 drugs predicted to target GPRC5B using DSigDB. (E) Molecular docking of the top predicted drug, Doramectin, with GPRC5B, showing the 3D binding conformation. RAW264.7 macrophage cells were cultured and divided into two groups: control (normal medium) and estrogen deprivation. (F) Representative images of RAW264.7 cells under control and estrogen-deprived conditions. (G) RT-qPCR analysis of GPRC5B mRNA levels and western blot analysis of protein expression in RAW264.7 cells under control and estrogen-deprived groups. (H) ELISA detection of secreted inflammatory cytokines in culture supernatants, including pro-inflammatory TNF-α and anti-inflammatory IL-10. (I, J) Effects of Doramectin treatment (0, 5, 10, 20 μM for 24–48 h) on GPRC5B expression in RAW264.7 cells, assessed by RT-qPCR (I) and Western blot (J) .

Journal: Frontiers in Immunology

Article Title: Integrated single-cell and experimental analyses implicate GPRC5B in macrophage senescence-related alterations in postmenopausal osteoporosis

doi: 10.3389/fimmu.2026.1890278

Figure Lengend Snippet: GPRC5B knockdown ameliorates PMO-associated phenotypes and reveals potential drug targets. GPRC5B-knockdown PMO mice were established and divided into three groups (n=5): PMO (23 months OVX model), PMO+shGPRC5B, and PMO+shGPRC5B+DLG1 inhibitor (DLG1i). The effects of GPRC5B knockdown on bone phenotype, macrophage senescence, and potential drug interactions were subsequently evaluated. (A) Western blot analysis of GPRC5B, DLG1, and Kv1.3 protein expression levels in primary bone marrow-derived macrophages from each group. (B) Representative three-dimensional reconstructed micro-CT images of mice femurs. (C) β-Gal staining of primary BMMs to assess cellular senescence. ***p < 0.001 vs. PMO; ###p < 0.001 vs. PMO+shGPRC5B. (D) Bar plot showing the scores of the top 20 drugs predicted to target GPRC5B using DSigDB. (E) Molecular docking of the top predicted drug, Doramectin, with GPRC5B, showing the 3D binding conformation. RAW264.7 macrophage cells were cultured and divided into two groups: control (normal medium) and estrogen deprivation. (F) Representative images of RAW264.7 cells under control and estrogen-deprived conditions. (G) RT-qPCR analysis of GPRC5B mRNA levels and western blot analysis of protein expression in RAW264.7 cells under control and estrogen-deprived groups. (H) ELISA detection of secreted inflammatory cytokines in culture supernatants, including pro-inflammatory TNF-α and anti-inflammatory IL-10. (I, J) Effects of Doramectin treatment (0, 5, 10, 20 μM for 24–48 h) on GPRC5B expression in RAW264.7 cells, assessed by RT-qPCR (I) and Western blot (J) .

Article Snippet: After blocking, membranes were incubated overnight at 4 °C with primary antibodies against GPRC5B (Thermo Fisher, MA5-63445), DLG1 (BD Biosciences, 610874), Kv1.3 (Alomone Labs, APC-101-B), and β-actin (Abcam, ab8226).

Techniques: Knockdown, Western Blot, Expressing, Derivative Assay, Micro-CT, Staining, Binding Assay, Cell Culture, Control, Quantitative RT-PCR, Enzyme-linked Immunosorbent Assay